A preclinical stage biopharmaceutical company with a mission to transform the cancer patient journey of radiation therapy by solving the global unmet need of radiation therapy side effects 

Scientific Discovery and Preclinical Studies

Cancer Patients and Cancer Survivors are suffering from their cancer and serious side effects caused by radiation therapy1


At MD Anderson Cancer Center Orlando (formerly affiliated with Orlando Health) board-certified radiation, surgical, medical oncologists and researchers discovered a use for cerium oxide nanoparticles to protect normal tissue during radiation


The proposed drugs generated from BioCurity's proprietary technology have been preclinically tested for multiple cancers including breast, lung, head & neck, prostate and colorectal cancers and published in peer-reviewed journals such as Nanomedicine


Designed to be effective without the risk of interfering with the efficacy of the targeted therapy dosage



1Benderitter, Marc et al. “Stem Cell Therapies for the Treatment of Radiation-Induced Normal Tissue Side Effects.” Antioxid Redox Signal. 2 (2014): 338-355

Oncology Supportive Care Drugs Under Development

The global cancer supportive care market is poised to reach $23 Billion by 2026 and is driven by the growing prevalence of cancer cases1


BioCurity’s proposed drugs generated from the Company’s cerium oxide nanoparticle technology designed to prevent radiation damage include:

  • Topical formulation for the protection of skin
  • Intravenous (IV) formulation for the protection of normal internal tissue

1Cancer Supportive Care Drugs Market Size, Share & Trends Analysis Report By Therapeutic Class (G-CSFs, Bisphosphonates, Antiemetics, Opioids, NSAIDs, ESAs), By Region, And Segment Forecasts, 2019 - 2026. Grand View Research. www.grandviewresearch.com/industryanalysis/cancer-supportive-care-drugs-market. 2019

Interests and Demand from Oncologists, Physicians and Healthcare Professionals

Physicians, patients, nonprofit organizations, hospitals, insurance companies and advocates for cancer patient support programs are familiar with the economic costs and wide ranging effects which the damage to normal tissue causes the patients whom are in treatment for their cancer

Print Print | Sitemap
© 2021 BioCurity Pharmaceuticals Inc. All Rights Reserved.